This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .
Growth hormone and body composition in children younger than 2 years with Prader-Willi syndrome.
OBJECTIVES To assess body composition of infants with Prader-Willi syndrome ( PWS ) by using deuterium dilution and investigating the efficacy of early institution of growth hormone ( GH ) therapy in increasing lean mass ( LM ) and preventing massive obesity . STUDY DESIGN One group of 11 children with PWS < 2 years before and during 30-month GH therapy ( GH group )  was compared with 6 infants administered only coenzyme Q(10 ) for 1 year ( Q10 group ) . LM adjusted for height ( LM(Ht ) ) and relative fat mass ( % FM(Age ) ) st and ard deviation scores ( SDS ) were calculated from data of 95 healthy children . RESULTS Initially , LM(Ht ) of all patients was below the normal average . LM(Ht ) decreased by -0.46 + /- 0.3 SD ( P=.03 ) per year in the Q10 group but rose by 0.25 + /- 0.3 SD ( P=.02 ) per year during GH therapy , normalizing after 30 months ( -0.70 + /- 1.0 SD ) . Despite low to normal weight for height ( WfH ) , % FM(Age ) was above the normal average ( GH group , 31.0 % + /- 4.5 % , Q10 group , 32.4 % + /- 9.5 % ) . In the Q10 infants , % FM(Age ) increased by 0.71 + /- 0.7 SD per year , whereas in the GH group , % FM(Age ) remained more stable up to 30 months . CONCLUSIONS Diminished LM(Ht ) found in infants with PWS further declines during the early years . Early institution of GH therapy lifts LM(Ht ) into the normal range and delays fat tissue accumulation
This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .